352 related articles for article (PubMed ID: 32619350)
1. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
[TBL] [Abstract][Full Text] [Related]
2. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
3. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
Wang S; Yao Y; Yao M; Fu P; Wang W
Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
[TBL] [Abstract][Full Text] [Related]
5. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
7. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
8. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
9. CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers.
Yi M; Peng C; Xia B; Gan L
Clin Breast Cancer; 2022 Feb; 22(2):e191-e198. PubMed ID: 34284965
[TBL] [Abstract][Full Text] [Related]
10. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
Yang M; Teng W; Qu Y; Wang H; Yuan Q
Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.
Gangapuram M; Mazzio EA; Redda KK; Soliman KFA
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299315
[TBL] [Abstract][Full Text] [Related]
12. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
[TBL] [Abstract][Full Text] [Related]
13. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
[TBL] [Abstract][Full Text] [Related]
14. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
15. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
[TBL] [Abstract][Full Text] [Related]
16. 1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel.
Modi K; Lawson S; Chen G; Tumuluri D; Rekhtman I; Kurtz M; Brailoiu GC; Chen QH; Lakshmikuttyamma A
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806551
[TBL] [Abstract][Full Text] [Related]
17. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
18. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
19. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
20. New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells.
Ciocan-Cartita CA; Jurj A; Zanoaga O; Cojocneanu R; Pop LA; Moldovan A; Moldovan C; Zimta AA; Raduly L; Pop-Bica C; Buse M; Budisan L; Virag P; Irimie A; Gomes Dias SM; Berindan-Neagoe I; Braicu C
J Exp Clin Cancer Res; 2020 Nov; 39(1):241. PubMed ID: 33187552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
